SCHEMBL19902393

SCHEMBL19902393

CN[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.41
AR P10275 5/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PARP1 P09874 2/20 0.40
CYP1A2 P05177 2/20 0.39
ROCK1 Q13464 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PRMT5 O14744 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 1/20 0.38
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
PARP2 Q9UGN5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789261 0.88 ATM (0.50) ROCK2ARATMNPSR1PARP1
SCHEMBL19902452 0.85 SMN1; SMN2 (0.45) ROCK2ATMNPSR1PARP1CYP1A2
SCHEMBL17454385 0.82 ROCK2 (0.56) ROCK2ARATMNPSR1PARP1
SCHEMBL17452509 0.82 ROCK2 (0.56) ROCK2ARATMNPSR1PARP1
SCHEMBL1786583 0.82 ATM (0.47) ROCK2ARATMNPSR1PARP1
SCHEMBL1786994 0.82 PRMT5 (0.48) ROCK2ARATMNPSR1PARP1
SCHEMBL19902689 0.81 ROCK2 (0.46) ROCK2CYP1A2ROCK1ALDH1A1CYP3A4
SCHEMBL19902690 0.81 SMN1; SMN2 (0.44) ROCK2PARP1CYP1A2ROCK1ALDH1A1
SCHEMBL19902312 0.81 PRMT5 (0.45) ROCK2ARATMNPSR1PARP1
SCHEMBL19902284 0.81 PRMT5 (0.45) ROCK2ARATMNPSR1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK2 3/4885AR 356/4885ATM 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.